08:20 AM EST, 02/12/2025 (MT Newswires) -- AnaptysBio ( ANAB ) said Wednesday that a phase 2b trial of its investigational drug rosnilimab to treat moderate-to-severe rheumatoid arthritis achieved its primary and secondary endpoints.

Patients in the study received either 100 milligram or 400 milligram doses of rosnilimab every four weeks, 600 milligrams every two weeks, or placebo, the company said.

The trial achieved its primary endpoint of a change from baseline for all three doses vs. placebo at week 12 and showed that the drug was safe and well-tolerated, the company said.

AnaptysBio ( ANAB ) shares were 23% higher in premarket activity.